
Alzamend Neuro (ALZN) Stock Forecast & Price Target
Alzamend Neuro (ALZN) Analyst Ratings
Bulls say
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company dedicated to creating novel treatments for neurodegenerative diseases and psychiatric disorders, with a specific focus on Alzheimer's disease. The company has reported positive top-line results from its studies in June 2023, signifying potential advancements in its drug pipeline, which includes innovative therapies such as AL001 and AL002. With an attractive current valuation, as highlighted by a net present value (NPV) analysis, the company presents significant upside potential, driven by the achievement of key milestones and the continuation of favorable data outcomes.
Bears say
Alzamend Neuro Inc reported a net loss of $2.7 million, translating to an earnings per share (EPS) of $(1.28), significantly worse than estimates of $(0.69). The company faces numerous threats to its financial success, including balance sheet and liquidity risks, potential failures in demonstrating safety and efficacy of its drug candidates, and challenges in obtaining regulatory approvals. Additionally, competitive pressures and shifting investor sentiment towards biotech stocks may further hinder Alzamend Neuro's growth prospects and overall market performance.
This aggregate rating is based on analysts' research of Alzamend Neuro and is not a guaranteed prediction by Public.com or investment advice.
Alzamend Neuro (ALZN) Analyst Forecast & Price Prediction
Start investing in Alzamend Neuro (ALZN)
Order type
Buy in
Order amount
Est. shares
0 shares